Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Taro Pharmaceutical Industries
|
| gptkbp:ceo |
gptkb:Dilip_Shanghvi
|
| gptkbp:employees |
over 30,000
|
| gptkbp:founded |
gptkb:1993
|
| gptkbp:global_presence |
Over 100 countries
|
| gptkbp:headquarters |
gptkb:Mumbai,_India
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sun Pharm Investments Inc.
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:market_cap |
$30 billion (2021)
|
| gptkbp:partnership |
gptkb:Abb_Vie
|
| gptkbp:products |
Generic drugs
|
| gptkbp:regulatory_compliance |
gptkb:FDA
gptkb:EMA |
| gptkbp:research_focus |
gptkb:Cardiology
gptkb:Oncology Neurology |
| gptkbp:revenue |
$4.5 billion (2020)
|
| gptkbp:stock_symbol |
SUNPHARMA
|
| gptkbp:subsidiary |
Sun Pharmaceutical Industries Ltd.
|
| gptkbp:website |
www.sunpharma.com
|
| gptkbp:bfsParent |
gptkb:Zenabis_Holdings_Inc.
|
| gptkbp:bfsLayer |
8
|